Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Avidity Biosciences (RNA) EBITDA: 2018-2024

Historic EBITDA for Avidity Biosciences (RNA) over the last 7 years, with Dec 2024 value amounting to -$319.5 million.

  • Avidity Biosciences' EBITDA fell 139.49% to -$174.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$555.1 million, marking a year-over-year decrease of 104.46%. This contributed to the annual value of -$319.5 million for FY2024, which is 52.59% down from last year.
  • As of FY2024, Avidity Biosciences' EBITDA stood at -$319.5 million, which was down 52.59% from -$209.4 million recorded in FY2023.
  • Over the past 5 years, Avidity Biosciences' EBITDA peaked at -$44.4 million during FY2020, and registered a low of -$319.5 million during FY2024.
  • Over the past 3 years, Avidity Biosciences' median EBITDA value was -$209.4 million (recorded in 2023), while the average stood at -$235.1 million.
  • Data for Avidity Biosciences' EBITDA shows a maximum YoY plummeted of 166.44% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Avidity Biosciences' EBITDA stood at -$44.4 million in 2020, then tumbled by 166.44% to -$118.2 million in 2021, then crashed by 49.34% to -$176.5 million in 2022, then dropped by 18.63% to -$209.4 million in 2023, then tumbled by 52.59% to -$319.5 million in 2024.